FY2025 EPS Estimates for Genmab A/S Boosted by HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for shares of Genmab A/S in a research note issued on Monday, November 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $1.89 per share for the year, up from their previous forecast of $1.78. HC Wainwright has a “Buy” rating and a $41.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.40 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.59 EPS, Q4 2026 earnings at $0.63 EPS and FY2026 earnings at $2.14 EPS.

Several other analysts have also issued reports on the company. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Tuesday, September 23rd. Finally, Truist Financial reiterated a “buy” rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $39.75.

Genmab A/S Stock Up 1.4%

GMAB stock opened at $29.06 on Tuesday. The company has a 50 day moving average of $29.69 and a two-hundred day moving average of $24.55. The company has a market cap of $18.66 billion, a price-to-earnings ratio of 12.37, a PEG ratio of 1.56 and a beta of 0.96. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $33.65.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 24.48%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. Headlands Technologies LLC lifted its stake in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after buying an additional 1,464 shares during the last quarter. Osaic Holdings Inc. lifted its position in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC boosted its holdings in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after acquiring an additional 603 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after purchasing an additional 1,070 shares during the last quarter. Finally, AlphaCore Capital LLC bought a new position in shares of Genmab A/S in the second quarter worth about $44,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.